Member Type: Diagnostic Companies
QIAGEN aquired DxS, a personalized healthcare company in September 2009 to create a Center of Excellence in Companion Diagnostics. QIAGEN works with pharmaceutical companies to support development of targeted cancer therapies by providing biomarkers and companion diagnostics.
Working primarily in oncology, their product portfolio includes real-time PCR assays for K-RAS, EGFR, B-RAF and PI3K genes, to aid doctors and drug companies select therapies for patients.
QIAGEN is active in more than 15 partnerships with pharmaceutical and large biotech companies in the field of personalized healthcare, including Astra Zeneca, Merck, Amgen, Bristol-Myers Squibb/ImClone Systems, Boehringer-Ingelheim and Pfizer.